Konza Technopolis to host Kenya’s first Biopharma Life Sciences park
Audio By Vocalize
The project, spearheaded by pan-African pharmaceutical company Apifa Biotech under a public-private partnership (PPP) framework with the Technopolis Development Authority, aims to strengthen local production of medicines and medical consumables while curbing Kenya’s reliance on pharmaceutical imports. The National Treasury granted approval for the initiative to proceed to the development phase in April 2026.
A consortium comprising global real estate and investment advisory firm Jones Lang LaSalle (JLL) and healthcare analytics company IQVIA has been selected to conduct the feasibility study. Backed by Swedfund’s funding, the study will assess the park’s technical requirements, commercial viability, investment structure, and implementation roadmap.
Technopolis Development Authority Chief Executive Officer John Paul Okwiri stated that the facility is key to positioning Konza Technopolis as a regional hub for biotechnology innovation and pharmaceutical manufacturing.
"The Biopharma Life Sciences Park will position Konza as an emerging centre for life sciences and pharmaceutical manufacturing, helping Kenya move from importing most of its medicines to producing them locally," Okwiri said.
Elsa Ekblom, Health Sector Lead at Swedfund’s Project Accelerator, noted that the grant funding will advance critical groundwork and create a clear pathway toward attracting long-term private investment into Kenya’s life sciences sector.
Apifa Biotech, a Kenyan-registered subsidiary of API for Africa (APIFA) focused on local production of active pharmaceutical ingredients (APIs) and essential medicines, will design, develop, and finance the facility.
Speaking at the milestone announcement alongside Apifa Biotech Board Chairman Dr. Gerald Macharia, Chief Executive Officer Dr. Keter said the partnership with Konza Technopolis, Swedfund, and the JLL-IQVIA consortium moves the company closer to establishing a world-class manufacturing hub serving the East African Community (EAC).
The development aligns with national policies aimed at locally manufacturing at least half of Kenya’s essential health products, as well as the African Union’s broader target of meeting 60 percent of the continent’s health product needs through local production by 2040.
Once operational, the park will provide shared infrastructure designed to foster collaboration among pharmaceutical manufacturers, researchers, technology firms, and investors.

Join the Discussion
Share your perspective with the Citizen Digital community.
No comments yet
This discussion is waiting for your voice. Be the first to share your thoughts!